Novo Nordisk Patent-Cliff Exposure & CMS Drug Spending Portfolio

Novo Nordisk (Plainsboro, NJ): 54 reconciled FDA prescription therapies, $24.88B 2024 CMS Part D & Medicaid spend, and 3 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterPlainsboro, NJ
Reconciled FDA Portfolio Therapies54
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2035-01-01
2024 CMS Total Public Spend$24.88B
2024 Medicare Part D Spend$18.57B
2024 Medicaid Spend$6.31B
California HCAI SB 17 Filings3 WAC filings (max 17.9% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novo Nordisk across sibling Meru public-data platforms.